Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Feb 07, 2020

Chugai Supports National Cancer Center Japan for an Investigator-Initiated Clinical Study Based on Patient-Requested Therapy System

  • Chugai will provide multiple drugs to support a clinical study based on the patient-requested therapy system to examine new therapeutic options for patients undergoing a comprehensive genomic profiling test

TOKYO, February 7, 2020 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that it has entered into an agreement with National Cancer Center Japan to support an investigator-initiated clinical study based on the patient-requested therapy system.

The clinical research program titled “the prospective trial of patient-proposed healthcare services with multiple targeted agent based on the result of gene profiling by multigene panel test” is led by National Cancer Center Hospital as a coordinating secretariat. The study aims to examine new therapeutic opportunities for patients with genetic alterations identified with comprehensive genomic profiling tests who have no treatment options available including approved drugs or clinical trials by utilizing the patient-requested therapy system. Advocating the objectives of the clinical study, Chugai will provide drugs in the study.

“The recent insurance coverage for the genomic analysis using next-generation sequencing (NGS) technology enabled allow us to select optimized cancer treatment for each patient. However, some patients cannot receive molecularly matched therapy due to lack of approved drugs even if gene alteration has been identified. We are very pleased that our products will help offer such patients therapeutic opportunities,” said Dr. Yasushi Ito, Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit. “Chugai will continue striving to promote advanced personalized healthcare to realize the optimal treatment for each patient as a leading company in oncology.”

For the press release (Japanese only) on the clinical study released by National Cancer Center Japan, please visit; https://www.ncc.go.jp/jp/information/pr_release/2019/20191002/index.html

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Toshiya Sasai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top